Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences

Rhea-AI Summary

Voyager Therapeutics (NASDAQ: VYGR) will release its Q2 2020 financial results and corporate updates on August 10, 2020, before U.S. markets open. The company is focused on gene therapy for severe neurological diseases and will participate in three virtual investor conferences from August 10 to August 12. These events highlight Voyager's commitment to advancing AAV gene therapy and its pipeline targeting therapies for diseases like Parkinson's and Huntington's.

Positive

• Participation in multiple investor conferences may enhance investor interest and visibility.
• Focus on developing treatments for severe neurological diseases, addressing significant unmet medical needs.

Negative

• None.

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporate updates on Monday, August 10, 2020, before the open of the U.S. financial markets.

Additionally, the company will participate in the following virtual investor conferences in August:

• BTIG Virtual Biotechnology Conference
  Monday, August 10 at 3:30 p.m. ET
  
  
• Wedbush PacGrow Healthcare Virtual Conference
  Tuesday, August 11 at 1:10 p.m. ET
  
  
• Canaccord Genuity 40^th Annual Growth Conference
  Wednesday, August 12 at 3:30 p.m. ET

The webcast sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.

Investor Relations:   
Paul Cox
VP, Investor Relations
857-201-3463
pcox@vygr.com   

Media:
Sheryl Seapy
W2Opure
949-903-4750
sseapy@purecommunications.com

FAQ

When will Voyager Therapeutics release its Q2 2020 financial results?

Voyager Therapeutics will report its Q2 2020 financial results on August 10, 2020, before the market opens.

What investor conferences will Voyager Therapeutics attend in August 2020?

Voyager will participate in the BTIG Virtual Biotechnology Conference on August 10, Wedbush PacGrow Healthcare Virtual Conference on August 11, and Canaccord Genuity 40th Annual Growth Conference on August 12.

What is the focus of Voyager Therapeutics?

Voyager Therapeutics focuses on developing gene therapies for severe neurological diseases, including Parkinson's and Huntington's diseases.